Nebivolol Generics [uk] (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management. Its dual action of β1‑blockade and nitric‑oxide mediated vasodilation makes it suitable for long‑term management of these conditions.

• Hypertension: Lowers both systolic and diastolic blood pressure, contributing to cardiovascular risk reduction and helping patients reach guideline‑recommended targets.
• Heart failure: Enhances left ventricular ejection, decreases heart rate, and lowers the risk of hospitalization in patients with chronic heart failure with reduced ejection fraction.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, reducing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric‑oxide synthase, increasing nitric‑oxide release which causes vasodilation of peripheral vessels. The combined effect lowers cardiac output and systemic vascular resistance, leading to decreased blood pressure and improved cardiac efficiency in heart failure. The nitric‑oxide pathway also improves endothelial function, contributing to the antihypertensive profile.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Headache: mild to moderate headache reported in some patients.
• Dizziness: transient dizziness, especially after the first dose or dose increase.
• Fatigue: generalized tiredness or reduced energy levels.
• Nasal congestion: mild nasal stuffiness or runny nose.

Serious or Rare Side Effects

• Bradycardia: excessively low heart rate requiring medical attention.
• Heart block: atrioventricular conduction disturbances.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing nebivolol, clinicians should consider several precautionary measures to ensure patient safety.

• Cardiovascular assessment: evaluate heart rate and blood pressure before initiating therapy.
• Concomitant β‑blockers: avoid combining with other β‑blockers to prevent excessive bradycardia.
• Asthma or COPD: use with caution in patients with reactive airway disease.
• Diabetes: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms.
• Liver impairment: dose adjustment may be required in moderate to severe hepatic dysfunction.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined β‑blockers: additive negative chronotropic effects may cause severe bradycardia.
• Calcium channel blockers (verapamil, diltiazem): increase nebivolol plasma levels, raising risk of hypotension.
• CYP2D6 inhibitors (paroxetine, fluoxetine): may elevate nebivolol concentrations.

Moderate Interactions (Monitor Closely)

• Antihypertensives: concurrent use may enhance blood pressure lowering, requiring dose titration.
• Diuretics: may potentiate orthostatic hypotension, especially during initiation.
• Antidiabetic agents: β‑blockade can mask hypoglycaemia signs, necessitating glucose monitoring.